These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36141631)

  • 21. Approaches for predicting long-term sickness absence. Re: Schouten et al. "Screening manual and office workers for risk of long-term sickness absence: cut-off points for the Work Ability Index".
    van Amelsvoort LGPM; Jansen NWH; Kant I
    Scand J Work Environ Health; 2015 May; 41(3):322-323. PubMed ID: 25639964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between partial sickness benefit and disability pensions: initial findings of a Finnish nationwide register study.
    Kausto J; Virta L; Luukkonen R; Viikari-Juntura E
    BMC Public Health; 2010 Jun; 10():361. PubMed ID: 20573207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.
    Simonsson O; Hendricks PS; Stenfors CU; Goldberg SB; Honk L; Osika W
    J Psychopharmacol; 2024 Jan; 38(1):110-115. PubMed ID: 38140891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of paid sick leave on worker absenteeism and health care utilization.
    Chen J; Meyerhoefer CD; Peng L
    Health Econ; 2020 Sep; 29(9):1062-1070. PubMed ID: 32592446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.
    VanderZwaag B; Garcia-Romeu A; Garcia-Barrera MA
    Ther Adv Psychopharmacol; 2024; 14():20451253241264812. PubMed ID: 39132012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
    Zeifman RJ; Singhal N; Breslow L; Weissman CR
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):436-451. PubMed ID: 33860173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sickness absence in the private sector of Greece: comparing shipyard industry and national insurance data.
    Alexopoulos EC; Merekoulias G; Tanagra D; Konstantinou EC; Mikelatou E; Jelastopulu E
    Int J Environ Res Public Health; 2012 Apr; 9(4):1171-81. PubMed ID: 22690189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sickness absence and associations with sociodemographic factors, health risk behaviours, occupational stressors and adverse mental health in 40,343 UK police employees.
    Parkes S; Irizar P; Greenberg N; Wessely S; Fear NT; Hotopf M; Stevelink SAM
    Epidemiol Psychiatr Sci; 2024 May; 33():e26. PubMed ID: 38712441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.